2014 Analysis of the Argentinean Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies
Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350.
2014 Analysis of the Argentinean Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the Argentinean cancer diagnostics market during the next five years. The report examines trends in the Argentinean cancer diagnostics market; reviews current and emerging tests; analyses potential applications of various diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.
Business Opportunities and Strategic Recommendations
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Market Segmentation Analysis
Technology Review
Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Assessments
Strategic assessments ofmajor suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R&D.
Contains 509 pages and 56 tables
2014 Analysis of the Argentinean Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the Argentinean cancer diagnostics market during the next five years. The report examines trends in the Argentinean cancer diagnostics market; reviews current and emerging tests; analyses potential applications of various diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Market Segmentation Analysis
- Market shares of major suppliers.
- Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:
- Hospitals
- Commercial/Private LaboratoriesCurrent and Emerging Products
- Review of over 200 current and emerging cancer diagnostic tests,including:
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.
Technology Review
Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Assessments
Strategic assessments ofmajor suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R&D.
Contains 509 pages and 56 tables
I. INTRODUCTION
II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS
1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE-SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
26. BIOCHEMICAL TUMOR MARKERS
ADA
B-Protein
PNP
5'-Nucleotidase
27. ONCOGENES
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. POLYPEPTIDE GROWTH FACTORS
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. IMMUNOHISTOCHEMICAL STAINS
33. EMERGING TUMOR MARKERS
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA 50
CA 72-4/TAG-72
CA 195
CA-242
CA-549
CAM 26
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA 93
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma 552
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor 1
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL 175
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG 12
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
B. INSTRUMENTATION REVIEW AND MARKET NEEDS
C. CURRENT AND EMERGING TECHNOLOGIES
1. Monoclonal and polyclonal antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular diagnostics
a. Technology Overview
b. Amplification Methods
4. Chromosome analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial intelligence
6. Flow cytometry
7. Two dimensional gel electrophoresis (2-dge)
8. Biosensors
9. Competing/complementing technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
D. PERSONAL TESTING
III. ARGENTINA: MARKET SIZE, GROWTH, AND MAJOR SUPPLIERS’ SHARES
X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. REAGENT KITS AND TEST SYSTEMS/PANELS
B. INSTRUMENTATION
C. COMPUTERS, SOFTWARE AND AUTOMATION
D. AUXILIARY PRODUCTS
XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
XII. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. INTERNAL DEVELOPMENT
B. COLLABORATIVE ARRANGEMENTS
C. UNIVERSITY CONTRACTS
D. DISTRIBUTION STRATEGIES
1. Marketing approaches
2. Product complexity
3. Customer preference
4. Established suppliers
5. Emerging suppliers
6. Major types of distributors
7. Market segmentation factor
XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. MARKET MATURITY
B. COST CONTAINMENT
C. COMPETITION
D. TECHNOLOGICAL EDGE AND LIMITATIONS
E. PATENT PROTECTION
F. REGULATORY CONSTRAINTS
G. DECENTRALIZED TESTING MARKET CHALLENGES
XIV. COMPETITIVE PROFILES
Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
XV. APPENDIXES: APPENDIX: MAJOR UNIVERSITIES AND RESEARCH
Centers Developing Cancer Diagnostic Technology and Applications
II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS
1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE-SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
26. BIOCHEMICAL TUMOR MARKERS
ADA
B-Protein
PNP
5'-Nucleotidase
27. ONCOGENES
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. POLYPEPTIDE GROWTH FACTORS
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. IMMUNOHISTOCHEMICAL STAINS
33. EMERGING TUMOR MARKERS
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA 50
CA 72-4/TAG-72
CA 195
CA-242
CA-549
CAM 26
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA 93
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma 552
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor 1
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL 175
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG 12
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
B. INSTRUMENTATION REVIEW AND MARKET NEEDS
C. CURRENT AND EMERGING TECHNOLOGIES
1. Monoclonal and polyclonal antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular diagnostics
a. Technology Overview
b. Amplification Methods
4. Chromosome analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial intelligence
6. Flow cytometry
7. Two dimensional gel electrophoresis (2-dge)
8. Biosensors
9. Competing/complementing technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
D. PERSONAL TESTING
III. ARGENTINA: MARKET SIZE, GROWTH, AND MAJOR SUPPLIERS’ SHARES
X. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. REAGENT KITS AND TEST SYSTEMS/PANELS
B. INSTRUMENTATION
C. COMPUTERS, SOFTWARE AND AUTOMATION
D. AUXILIARY PRODUCTS
XI. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
XII. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. INTERNAL DEVELOPMENT
B. COLLABORATIVE ARRANGEMENTS
C. UNIVERSITY CONTRACTS
D. DISTRIBUTION STRATEGIES
1. Marketing approaches
2. Product complexity
3. Customer preference
4. Established suppliers
5. Emerging suppliers
6. Major types of distributors
7. Market segmentation factor
XIII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. MARKET MATURITY
B. COST CONTAINMENT
C. COMPETITION
D. TECHNOLOGICAL EDGE AND LIMITATIONS
E. PATENT PROTECTION
F. REGULATORY CONSTRAINTS
G. DECENTRALIZED TESTING MARKET CHALLENGES
XIV. COMPETITIVE PROFILES
Abbott
AdnaGen
Agilent Technologies
Applied Gene Technologies
Arca/Nuvelo
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Epigenomics
Enterix
Enzo Biochem
Exact Sciences
Fujirebio/Innogenetics
Guided Therapeutics
Hologic/Gen-Probe
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Ortho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen/Ipsogen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
XV. APPENDIXES: APPENDIX: MAJOR UNIVERSITIES AND RESEARCH
Centers Developing Cancer Diagnostic Technology and Applications
LIST OF TABLES
Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
EXECUTIVE SUMMARY TABLE:
Argentina, Total Cancer Diagnostic Test Volume and Sales Forecast by Market Segment
Argentina, Laboratories Performing Cancer Diagnostic Tests by Market Segment
Argentina, Total Estimated Cancer Diagnostic Test Volume Forecast by Market Segment
Argentina, All Market Segments Estimated Cancer Diagnostic Test Volume Forecast
Argentina, Hospital Laboratories Estimated Cancer Diagnostic Test Volume Forecast by Test
Argentina, Commercial/Private Laboratories Estimated Cancer Diagnostic Test Volume Forecast
Argentina, Total Estimated Cancer Diagnostic Sales Forecast by Market Segment
Argentina, All Market Segments Estimated Cancer Diagnostic Sales Forecast by Test
Argentina, Hospital Laboratories Estimated Cancer Diagnostic Sales Forecast by Test
Argentina, Commercial/Private Laboratories Estimated Cancer Diagnostics Market Forecast by Test
Argentina, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market
Argentina, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment
Argentina, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Progesterone Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
Argentina, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Cancer Diagnostics Market Estimated Shares Of Major Suppliers
Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
EXECUTIVE SUMMARY TABLE:
Argentina, Total Cancer Diagnostic Test Volume and Sales Forecast by Market Segment
Argentina, Laboratories Performing Cancer Diagnostic Tests by Market Segment
Argentina, Total Estimated Cancer Diagnostic Test Volume Forecast by Market Segment
Argentina, All Market Segments Estimated Cancer Diagnostic Test Volume Forecast
Argentina, Hospital Laboratories Estimated Cancer Diagnostic Test Volume Forecast by Test
Argentina, Commercial/Private Laboratories Estimated Cancer Diagnostic Test Volume Forecast
Argentina, Total Estimated Cancer Diagnostic Sales Forecast by Market Segment
Argentina, All Market Segments Estimated Cancer Diagnostic Sales Forecast by Test
Argentina, Hospital Laboratories Estimated Cancer Diagnostic Sales Forecast by Test
Argentina, Commercial/Private Laboratories Estimated Cancer Diagnostics Market Forecast by Test
Argentina, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market
Argentina, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Lymphocyte Subtyping Test Volume And Diagnostics Sales Forecast by Market Segment
Argentina, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Progesterone Receptor Test Volume And Diagnostics Sales Forecast by Market Segment
Argentina, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
Argentina, Cancer Diagnostics Market Estimated Shares Of Major Suppliers
